Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation

Diabetic Medicine

Volumn 15, Issue 7, 1998, Pages 539-553

  Alberti, K G M M ^a,c   Zimmet, P Z ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Classification; Diabetes mellitus; Diagnosis; Gestational diabetes mellitus; Type 2 diabetes; Type I diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID; NICOTINIC ACID; PENTAMIDINE; THIAZIDE DIURETIC AGENT; THYROID HORMONE; VACOR;

ARTICLE; AUTOIMMUNITY; CONSULTATION; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIET RESTRICTION; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PREDICTION; PREGNANCY DIABETES MELLITUS; WORLD HEALTH ORGANIZATION;

AUTOIMMUNE DISEASES; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES, GESTATIONAL; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MUTATION; PREGNANCY; REFERENCE VALUES; WORLD HEALTH ORGANIZATION;

EID: 0031851293     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S     Document Type: Article

References (93)

1. WHO Expert Committee on Diabetes Mellitus. Second Report. Technical Report Series 646. Geneva: WHO, 1980.
2. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
3. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series 727. Geneva: WHO, 1985.
4. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
5. Finch CF, Zimmet PZ, Alberti KGMM. Determining diabetes prevalence: a rational basis for the use of fasting plasma glucose concentrations? Diabetic Med 1990; 7: 603-610.
6. McCance DR, Hanson RL, Charles MA, Jacobsson LTH, Pettitt DJ, Bennett PH et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. Br Med J 1994; 308: 1323-1328.
7. 1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785-791.
8. Charles MA, Balkau B, Vauzelle-Kervoeden F, Thibult N, Eschwège E. Revision of diagnostic criteria for diabetes (Letter). Lancet 1996; 348: 1657-1658.
9. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Comparison of diabetes diagnostic categories in the US population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care 1997; 20: 1859-1862.
10. Ramachandran A, Snehalatha C, Latha E, Vijay V. Evaluation of the use of fasting plasma glucose as a new diagnostic criterion for diabetes in Asian Indian population (Letter). Diabetes Care 1998; 21: 666-667.
11. Kuzuya T, Matsuda A. Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 1997; 20: 219-220.
12. Hoet JJ, Tripathy BB, Rao RH, Yajnik CS. Malnutrition and diabetes in the tropics. Diabetes Care 1996; 19: 1014-1017.
13. Tripathy BB, Samal KC. Overview and consensus statement on diabetes in tropical areas. Diabetes Metab Rev 1997; 13: 63-76.
14. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Gareeboo H, Hemraj F, et al. IFG or IGT: what best predicts future diabetes? A view of the new ADA recommendations. Diabetes 1998 (in press).
15. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: the Whitehall Study. Lancet 1980; i: 1373-1376.
16. Alberti KGMM. The clinical implications of impaired glucose tolerance. Diabetic Med 1996; 13: 927-937.
17. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
18. McCance DR, Hanson RE, Pettitt DJ, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus - do we need new criteria? Diabetologia 1997; 40: 247-255.
19. Zimmet PZ, Tuomi T, Mackay R, Rowley MJ, Knowles W, Cohen M, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabetic Med 1994; 11: 299-303.
20. Humphrey ARG, McCarty DJ, Mackay IR, Rowley MJ, Dwyer T, Zimmet P. Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus. Diabetic Med 1998; 15: 113-119.
21. Japan and Pittsburgh Childhood Diabetes Research Groups. Coma at onset of young insulin-dependent diabetes in Japan: the result of a nationwide survey. Diabetes 1985; 34: 1241-1246.
22. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Diabetes Care 1995; 18: 1050-1064.
23. Willis JA, Scott RS, Brown LJ, Forbes LV, Schmidli RS, Zimmet PZ, et al. Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Res Clin Pract 1996; 33: 89-97.
24. Hother-Nielsen O, Faber O, Sørensen NS, Beck-Nielsen H. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 1988; 11: 531-537.
25. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, et al. Predicting type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45: 926-933.
26. Molbak AG, Christau B, Marner B, Borch-Johnsen K, Nerup J. Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabetic Med 1994; 11: 650-655.
27. Betterle C, Zanette F, Pedini B, Presotto F, Rapp LB, Monsciotti CM, et al. Clinical and subclinical organ-specific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first-degree relatives. Diabetologia 1983; 26: 431-436.
28. McLarty DC, Athaide I, Bottazzo CF, Swai ABM, Alberti KGMM. Islet cell antibodies are not specifically associated with insulin-dependent diabetes in rural Tanzanian Africans. Diabetes Res Clin Pract 1990; 9: 219-224.
29. Ahrén B, Corrigan CB. Intermittent need for insulin in a subgroup of diabetic patients in Tanzania. Diabetic Med 1984; 2: 262-264.
30. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. In: Alberti KGMM, Zimmet P, DeFronzo RA, eds. International Textbook of Diabetes Mellitus, 2nd edn. Chichester: Wiley, 1997: 635-712.
31. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes. Prospective Study of Pima Indians. N Engl J Med 1993; 329: 1988-1992.
32. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, et al. Prevalence and determinants of glucose intolerance in a Dutch population. The Hoorn Study. Diabetes Care 1995; 18: 1270-1273.
33. Harris MI. Undiagnosed NIDDM; clinical and public health issues. Diabetes Care 1993; 16: 642-652.
34. Campbell PJ, Carlson MG. Impact of obesity on insulin action in NIDDM. Diabetes 1993; 42: 405-410.
35. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven C. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 1985; 248: E286-E291.
36. Kissebah AH, Vydelingum N, Murray R, Evans DF, Hartz AJ, Kalkhoff RK, et al. Relationship of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254-260.
37. Banerji MA, Chaiken RI, Huey H, Tuomi T, Norin AJ, MacKay IR, et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4: flatbush diabetes. Diabetes 1994; 43: 741-745.
38. Umpierrez GE, Casals MMC, Cebhardt SSP, Mixon PS, Clark WS, Phillips LS. Diabetic ketoacidosis in obese African-Americans. Diabetes 1995; 44: 790-795.
39. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate tor insulin resistance. N Engl J Med 1996; 334: 777-784.
40. Simonson DC, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 1984; 33: 838-845.
41. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17: 30-36.
42. Zimmet PZ. Kelly West Lecture 1991: challenges in diabetes epidemiology: from West to the rest. Diabetes Care 1992; 15: 232-252.
43. Harris MI, Cowie CC, Stern MP, Boyko ES, Reiber GE, Bennett PH, eds. Diabetes in America, 2nd edn. NIH publ. no. 95-1468. Washington DC: US Government Printing Office, 1995.
44. Valle T, Tuomilehto J, Eriksson J. Epidemiology of NIDDM in Europids. In: Alberti KGMM, Zimmet P, DeFronzo RA, eds. International Textbook of Diabetes Mellitus, 2nd edn. Chichester: Wiley, 1997: 125-142.
45. de Courten M, Bennett PH, Tuomilehto J, Zimmet P. Epidemiology of NIDDM in Non-Europids. In: Alberti KGMM, Zimmet P, DeFronzo RA, eds. International Textbook of Diabetes Mellitus. 2nd edn. Chichester: Wiley, 1997: pp 143-170.
46. Knowler WC, Nelson RG, Saad M, Bennett PH, Pettitt DJ. Determinants of diabetes mellitus in the Pima Indians. Diabetes Care 1993; 16: 216-227.
47. Byrne MM, Sturis J, Menzel S, Yamagata K, Fajans SS, Dronsfield MJ, et al. Altered insulin secretory response to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY 3 on chromosome 20. Diabetes 1996; 45: 1503-1510.
48. Clement K, Pueyo ME, Vaxillaire M, Rakotoambinina B, Thuillier F, Passa P, et al. Assessment of insulin sensitivity in glucokinase-deficient subjects. Diabetologia 1996; 39: 82-90.
49. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY 3). Nature 1996; 384: 455-458.
50. Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes. Nature 1992; 356: 162-164.
51. Vionnet N, Stoffel M, Takeda J, Yasuda K, Bell GI, Zouali H, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes. Nature 1992; 356: 721-722.
52. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, et al. Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY 1). Nature 1996; 384: 458-460.
53. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nature Genetics 1997; 117: 138-139.
54. Walker M, Turnbull DM. Mitochondrial related diabetes: a clinical perspective. Diabetic Med 1997; 14: 1007-1009.
55. Johns DR. Mitochondrial DNA and disease. N Engl J Med 1995; 333: 638-644.
56. Gruppuso PA, Gorden P, Kahn CR, Cornblath M, Zeller WP, Schwartz R. Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin. N Engl J Med 1984; 311: 629-634.
57. Robbins DC, Shoelson SE, Rubenstein AH, Tager HS. Familial hyperproinsulinemia: two cohorts secreting indistinguishable type II intermediates of proinsulin conversion. J Clin Invest 1984; 73: 714-719.
58. Haneda M, Polonsky KS, Bergenstal RM, Jaspan JB, Shoelson SE, Blix PM, et al. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med 1984; 310: 1288-1294.
59. Sanz N, Karam JH, Horita S, Bell GI. Prevalence of insulin-gene mutations in non-insulin-dependent diabetes mellitus. N Engl J Med 1986; 314: 1322-1323.
60. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans. N Engl J Med 1976; 294: 739-745.
61. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41: 1473-1490.
62. Gullo L, Pezzilli R, Morselli-Labate AM, and the Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994; 331: 81-84.
63. Larsen S, Hilsted J, Tronier B, Worning H. Metabolic control and B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis. Metabolism 1987; 36: 964-967.
64. Permert J, Larsson J, Westermark GT, Herrington MK, Christmanson L, Pour PM et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994; 330: 313-318.
65. Moran A, Pyzdrowski KL, Weinreb J, Kahn BH, Smith SA, Adams KS, et al. Insulin sensitivity in cystic fibrosis. Diabetes 1944; 43: 1020-1026.
66. Phelps G, Chapman I, Hall P, Braund W, Mackinnon M. Prevalence of genetic haemochromatosis among diabetic patients. Lancet 1989; ii: 233-234.
67. Yajnik CS, Shelgikar KM, Naik SS, Kanitkar SV, Orskov H, Alberti KGMM, et al. The ketoacidosis-resistance in fibro-calculous-pancreatic-diabetes. Diabetes Res Clin Pract 1992; 15: 149-156.
68. MacFarlane IA. Endocrine diseases and diabetes mellitus. In: Pickup JC, Williams G, eds. Textbook of Diabetes, 2nd edn. Oxford: Blackwell, 1997: pp 64.1-64.20.
69. Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR, Raskin P, et al. Somatostatinoma syndrome. N Engl J Med 1974; 301: 285-242.
70. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965; 273: 1135-1143.
71. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med 1943; 118: 529-540.
72. O'Byrne S, Feely J. Effects of drugs on glucose tolerance in non-insulin-dependent diabetes (parts I and II). Drugs 1990; 40: 203-219.
73. Gallanosa AG, Spyker DA, Curnow RT. Diabetes mellitus associated with autonomic and peripheral neuropathy after Vacor poisoning: a review. Clin Toxicol 1981; 18: 441-449.
74. Esposti MD, Ngo A, Myers MA. Inhibition of mitochondrial complex I may account for IDDM induced by intoxication with rodenticide Vacor. Diabetes 1996; 45: 1531-1534.
75. Assan R, Perronne C, Assan D, Chotard L, Mayaud C, Matheron S, et al. Pentamidine-induced derangements of glucose homeostasis. Diabetes Care 1995; 18: 47-55.
76. Forrest JA, Menser MA, Burgess JA. High frequency of diabetes mellitus in young patients with congenital rubella. Lancet 1971; ii: 332-334.
77. King ML, Bidwell D, Shaikh A, Voller A, Banatvala JE. Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type 1) diabetes mellitus. Lancet 1983; i: 1397-1399.
78. Karjalainen J, Knip M, Hyoty H, Linikki P, Ilonen J, Kaar M-L, et al. Relationship between serum insulin antibodies, islet cell antibodies and Coxsackie-B4 and mumps virus-specific antibodies at the clinical manifestation of type 1 (insulin-dependent) diabetes. Diabetologia 1988; 31: 146-152.
79. Pak CY, Eun H, McArthur RG, Yoon J. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988; ii: 1-4.
80. Hirata Y, Ishizu H, Ouchi N, et al. Insulin autoimmunity in a case of spontaneous hypoglycaemia. J Jpn Diabet Soc 1970; 13: 312-320.
81. Bodansky HJ, Grant PJ, Dean BM, McNally J, Bottazzo GF, Hambling MH, et al. Islet-cell antibodies and insulin autoantibodies in association with common viral infections. Lancet 1986; ii: 1351-1353.
82. Solimena M, De Camilli P. Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 1991; 14: 452-457.
83. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis (Letter). Lancet 1992; 340: 548.
84. Flier JS. Lilly Lecture: syndromes of insulin resistance: from patient to gene and back again. Diabetes 1942; 41: 1207-1219.
85. Kahn CR, Baird KL, Flier JS, Jarrett DB. Effects of autoantibodies to the insulin receptor on isolated adipocytes. J Clin Invest 1977; 60: 1094-1106.
86. Tsokos GC, Gorden P, Antonovych T, Wilson CB, Balow JE. Lupus nephritis and other autoimmune features in patients with diabetes mellitus due to autoantibody to insulin receptors. Ann Intern Med 1985; 102: 176-181.
87. Barrett TG, Bundey SE, Macleod AF. Neurodogeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995; 346: 1458-1463.
88. Stern MP. The insulin resistance syndrome. In: Alberti KGMM, Zimmet P, DeFronzo RA, eds. International Textbook of Diabetes Mellitus, 2nd edn. Chichester: Wiley, 1997: 255-283.
89. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome (Syndrome X). Diabetes 1992; 41: 715-722.
90. Kaplan NM. The deadly quartet: upper body adiposity, glucose intolerance, hypertriglyceridaemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
91. European Arterial Risk Policy Group on behalf of the International Diabetes Federation (European Region). A strategy for arterial risk assessment and management in Type 2 (non-insulin-dependent) diabetes. Diabetic Med 1997; 14: 611-621.
92. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M. Cardiovascular disease risk factors as predictors of Type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia 1993; 36: 553-559.
93. Eriksson KF, Lindegärde F. Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 1941; 34: 891-898.